E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Moderate to severe Ulcerative colitis or moderate to severe Crohn's disease |
|
E.1.1.1 | Medical condition in easily understood language |
Ulcerative colitis or Crohn's disease |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Digestive System Diseases [C06] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10045365 |
E.1.2 | Term | Ulcerative colitis |
E.1.2 | System Organ Class | 100000004856 |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10011400 |
E.1.2 | Term | Crohn's colitis |
E.1.2 | System Organ Class | 100000004856 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the efficacy and dose response of 2 different maintenance dose regimens of TEV-48574 subcutaneous (sc) administered every 2 weeks (Q2W) in adult patients with IBD (UC or CD) as assessed by maintenance of clinical remission (UC) and endoscopic response (CD) at week 24. |
|
E.2.2 | Secondary objectives of the trial |
To evaluate the efficacy and dose response of 2 different maintenance dose regimens of TEV-48574 sc administered Q2W in adult patients with IBD (moderate to severe UC or CD) as assessed by multiple standard measures at week 24.
Other: - to evaluate the safety and tolerability of 2 different dose regimens of TEV-48574 - to evaluate the immunogenicity of 2 different dose regimens of TEV-48574
Exploratory objectives include: - to evaluate association among exploratory biomarkers and clinical efficacy of TEV-48574 in adult patients with IBD (UC or CD) - to obtain trough serum TEV-48574 concentrations, to evaluate pharmacokinetics, and, if data allow, to evaluate the pharmacokinetics/pharmacodynamics relationship of 2 different dose regimens of TEV-48574 sc. - to evaluate the effect of genetic polymorphisms on clinical efficacy in adult patients with IBD (UC or CD). |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
a. Adults of male and female sex (without restrictions on gender) who at the time of informed consent achieved clinical response and/or clinical remission in the 14-week TV48574-IMM-20036 DRF study - Clinical response assessed by decrease from baseline in modified (9-point rectal bleeding, stool frequency, and endoscopy) Mayo score by ≥2 points and at least 30%, with a decrease in rectal bleeding subscore of ≥1 point or an absolute subscore of 0 or 1 at week 14 of the of the TV48574-IMM-20036 DRF study in patients with moderate to severe UC . - Clinical remission at week 14 of the TV48574-IMM-20036 DRF study in patients with moderate to severe UC. Clinical remission is a modified (9-point rectal bleeding, stool frequency, and endoscopy) Mayo score of ≤2 points, which is defined by: • stool frequency subscore of 0 or 1, • rectal bleeding subscore of 0, and • endoscopic subscore of 0 or 1, where a score of 1 does not include “friability” - Clinical response assessed by ≥100-point decrease in Crohn’s Disease Activity Index (CDAI) score from baseline week 14 of the TV48574-IMM-20036 DRF study in patients with moderate to severe CD - Clinical remission defined as a CDAI score <150 at week 14 of the TV48574-IMM- 20036 DRF study in patients with moderate to severe CD b. Patients who are women of childbearing potential (WOCBP) should have a negative β- human chorionic gonadotropin test result and practice a highly effective method of birth control. • Male patients (including vasectomized) with WOCBP partners should use condoms after the first IMP administration and throughout the study c. The patient must be willing and able to comply with study restrictions and to remain at the investigational center for the required duration during the study period, and willing to return to the investigational center for further visits, as applicable, and the follow-up procedures and assessments as specified in this protocol |
|
E.4 | Principal exclusion criteria |
a. Patients who discontinued the TV48574-IMM-20036 DRF study before scheduled week 14 visit (any reason including lack of efficacy, safety, or personal reasons) and patients who didn’t meet the definition of clinical response or clinical remission based on their DRF week 14 assessment b. The patient has any concomitant conditions or treatments that could interfere with study conduct, influence the interpretation of study observations/results, or put the patient at increased risk during the study as judged by the investigator and/or the clinical study physician. c. Diagnosis of indeterminate colitis, ischemic colitis, radiation colitis, diverticular disease associated with colitis, or microscopic colitis. d. Patient has colonic dysplasia or neoplasia, toxic megacolon, primary sclerosing cholangitis, known non-passable colonic stricture, presence of colonic or small bowel stoma, presence of non-passable colonic or small bowel obstruction or resection preventing the endoscopy procedure, or fulminant colitis. e. Presence of active enteric infections (positive stool culture) or a history of serious infection (requiring parenteral antibiotic and/or hospitalization) within 4 weeks prior to the first study visit. f. Patient anticipates requiring major surgery during this study. g. A history of an opportunistic infection (eg, cytomegalovirus retinitis, Pneumocystis carinii, or aspergillosis). h. A history of more than 1 herpes zoster episode or multimetameric herpes zoster. i. A history of or ongoing chronic or recurrent serious infectious disease (eg, infected indwelling prosthesis or osteomyelitis). j. Current or history of chronic liver or biliary disease (with the exception of Gilbert’ syndrome, asymptomatic gallstones or uncomplicated fatty liver disease) or alanine aminotransferase (ALT) >2x upper limit of normal (ULN) and bilirubin >1.5x ULN (isolated bilirubin >1.5x ULN is acceptable if bilirubin is fractionated and direct bilirubin <35%) at screening. k. Absolute neutrophil count <1.5x109/L or Hemoglobin <8 g/dL or lymphocyte count <0.8x109/L or platelet count <100,000/mL l. The patient has QTc>480 ms m. Patients with clinical symptoms that may indicate coronavirus disease 2019 (COVID-19) infection, and/or patients who, in the investigator’s opinion, were at high risk of exposure to COVID-19 within 6 weeks before the first study visit, will be tested for active COVID- 19 infection and will be excluded if they test positive for COVID-19. Patients who were admitted to an intensive care unit during a prior COVID-19 infection, patients who contracted or recovered from COVID-19 during the transition from DRF to LTE study, or patients with long-term COVID-19 symptoms are excluded from the study. n. The patient is currently pregnant or lactating or is planning to become pregnant or to lactate during the study or for at least 50 days after administration of the last dose of IMP in case of early termination. Any woman becoming pregnant during the study will be withdrawn from the study. o. The patient has a known hypersensitivity to the IMP and/or excipients. p. Presence of a transplanted organ. q. A history of malignancy within the last 5 years (exception: basal cell carcinoma or in situ carcinoma of the cervix if successful curative therapy occurred r. Patient has or is receiving any of the following therapies during the DRF study and/or within the transition period from the DRF study to the LTE study - The patient is currently using any systemic immunosuppressant or immunomodulatory biologic or nonbiologic - >9 mg/day of oral budesonide or >20 mg/day prednisone or equivalent - Topical (rectal) treatment of 5-aminosalicylic acid (5-ASA) or intravenous, intramuscular (parenteral), or enema/suppository administration of corticosteroids - Biologics including anti-TNF inhibitors, anti-integrin inhibitors, and anti-IL- 12/23 inhibitors - Small molecules including janus kinase (JAK) inhibitors, or sphingosine-1- phosphate (S1P) receptor modulators - Other investigational procedures or products excluding IMP - Live vaccine. Inactivated vaccines (including approved inactivated COVID-19 vaccines) should preferably be completed 14 days before first IMP dosing. If administered during the study, it is recommended to be at least 3 days before and after IMP administration, or as required by local country regulations s. Current or history (within 2 years) of serious psychiatric disease or alcohol or drug abuse t. Patients with incurable diseases, persons in nursing homes, and patients incapable of giving informed consent u. The patient is either an employee or an immediate relative of an employee of the sponsor or of any of the clinical investigational centers participating in the study |
|
E.5 End points |
E.5.1 | Primary end point(s) |
-Clinical remission based on modified (9-point rectal bleeding, stool frequency, and endoscopy) Mayo score of ≤2 points defined by a stool frequency subscore of 0 or 1, rectal bleeding subscore of 0, and an endoscopic subscore of 0 or 1, where a score of 1 does not include “friability” at week 24 in patients with UC - Endoscopic response, defined as a decrease in Simple Endoscopic Score for Crohn’s Disease (SES-CD) of at least 50% from DRF study baseline at week 24 in patients with CD |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
The secondary efficacy endpoints are as follows: - Clinical response, based on modified (9-point rectal bleeding, stool frequency, and endoscopy) Mayo score of at least 2 points AND at least a 30% reduction from DRF study baseline with either a decrease in rectal bleeding subscore of at least 1 or an absolute rectal bleeding subscore of less than or equal to 1 at week 24 in patients with UC - Endoscopic improvement from DRF study baseline based on Mayo endoscopic subscore of 0 or 1 at week 24 in patients with UC - Endoscopic remission based on Mayo endoscopic subscore of 0 at week 24 in patients with UC - Clinical response defined as decrease from DRF study baseline of atleast 50% in 2-item patient-reported outcome (PRO2; rectal bleeding and stool frequency) at weeks 0, 4, 8, 10, 12, 16, 20, and 24 in patients with UC - Clinical remission based on PRO2 (rectal bleeding=0 and stool frequency=0) at weeks 0, 4, 8, 10, 12, 16, 20 and 24 in patients with UC - Histological remission based on Robarts Histopathology Index (RHI ≤5) at week 24 in patients with UC - Histological remission based on Geboes index score ≤3.1 in patients with UC - Clinical response based on Crohn’s Disease Activity Index (CDAI): ≥100-point decrease in CDAI score from DRF study baseline at week 24 in patients with CD at weeks 0, 4, 8, 10, 12, 16, 20 and 24 - Clinical remission based on CDAI score <150 at week 0, 4, 8, 10, 12, 16, 20 and 24 in patients with CD - Endoscopic remission based on SES-CD: SES-CD score of 0-2, or SES-CD score of 0-4, with no individual sub score >1 at week 24 in patients with CD - Clinical response defined as decrease in PRO2 from DRF study baseline of at least 50% in PRO2 at weeks 0, 4, 8, 10, 12, 16, 20 and 24 in patients with CD - Clinical remission based on PRO2 (abdominal pain ≤1 and stool frequency ≤3) at weeks 0, 4, 8, 10, 12, 16, 20 and 24 in patients with CD - Endoscopic response, defined as a decrease in modified multiplier (MM)-SES-CD of >50% from DRF study baseline at week 24 in patients with CD - Histologic response (≥50% decrease) in Global Histologic Activity Score from DRF study baseline at week 24 in patients with CD
Other secondary endpoints include: Safety and tolerability measures/parameters as follows: - Frequency of adverse events - Change from baseline (LTE baseline) in clinical laboratory test results (serum chemistry, hematology, and urinalysis) - Change from baseline (LTE baseline) in vital signs measurements (blood pressure, pulse rate, body temperature, and respiratory rate) - Change from baseline (LTE baseline) in 12-lead electrocardiogram (ECG) findings - Use of concomitant medication - Number (%) of patients who stopped the IMP due to adverse events - Local tolerability at the injection site - Device-related adverse events and malfunctions (for the commercial sc infusion system)
Immunogenicity endpoints as follows: - Treatment-emergent anti-drug antibody (ADA) results and responses: change from baseline (DRF study) and throughout the study - Neutralizing ADA in ADA positive patients throughout the study. - Impact of the presence of ADAs on pharmacokinetics and clinical safety will be assessed if applicable
Exploratory endpoints include: - Change from DRF study baseline and from LTE baseline at weeks 4, 8, 14, 20 and 24 in select serum resident pharmacodynamic markers - Change from DRF study baseline and from LTE baseline in serum and/or gastrointestinal (GI) tissue markers of GI tissue condition at weeks 4, 8, 14, 20 and 24 for serum; at week 24 for tissue - Change from DRF study baseline and from LTE baseline at week 24 in GI tissue transcriptome - Change from DRF study baseline and from LTE baseline in fecal calprotectin at weeks 4, 8, 14, 20 and 22 - Change from DRF study baseline and from LTE baseline in high sensitivity C-reactive protein (hsCRP) at weeks 4, 8, 14, 20 and 24 - Change from DRF study baseline and from LTE baseline in serum free and total TL1A at weeks 0, 4, 8, 14, 20 and 24 - Change from DRF study baseline and from LTE baseline at week 24 in GI tissue TL1A expression - Change from DRF study baseline and from LTE baseline in UC-100 at week 24 in patients with UC - Trough serum TEV-48574 concentrations throughout the study (sparse sampling) - If performed, population pharmacokinetic analysis results may be reported separately from the main study results. - If performed, pharmacokinetics/pharmacodynamics modeling resultswill be reported separately from the main study results.
Primary and additional efficacy endpoints may be included. - If performed, pharmacogenetic analysis results will be reported separately from the main study results. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
The tested drug given at one dose is compared to a different dose of the same product. |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 88 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Canada |
Israel |
United States |
Austria |
France |
Poland |
Bulgaria |
Spain |
Czechia |
Germany |
Italy |
Belgium |
Hungary |
Norway |
Slovakia |
United Kingdom |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 1 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 6 |